| Symbol | AYTU |
|---|---|
| Name | AYTU BIOPHARMA, INC |
| Sector | HEALTH CARE |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 7900 E. UNION AVENUE, DENVER, CO 80237 |
| Telephone | (720) 437-6580 |
| Fax | — |
| — | |
| Website | https://www.aytubio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Aytu BioPharma is a pharmaceutical company focused on commercializing novel therapeutics. The companys prescription products include Adzenys XR-ODT(R) (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT(R) (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal(R) ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor(R) and Tri-Vi-Flor(R), two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - AYTU BIOPHARMA, INC <b>Filed:</b> 2026-02-17 <b>AccNo:</b> 0000935836-26-000109 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G/A - AYTU BIOPHARMA, INC <b>Filed:</b> 2026-02-13 <b>AccNo:</b> 0001535264-26-000010 <b>Size:</b> 8 KB
Read moreAytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Read more(30% Negative) Aytu BioPharma Inc. (AYTU) Reports Q1 2026 Financial Results
Read moreAytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
Read moreAytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
Read moreAytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo Oral Tablet | DRUG | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT07169162 |
| ADZENYS XR-ODT | DRUG | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT07169162 |
| Placebo | DRUG | Phase PHASE3 | Vascular Ehlers-Danlos Syndrome | SUSPENDED | NCT05463679 |
| Enzastaurin | DRUG | Phase PHASE3 | Vascular Ehlers-Danlos Syndrome | SUSPENDED | NCT05463679 |
| Sham Control Catheter | DEVICE | Approved | COVID-19 Pneumonia | WITHDRAWN | NCT05166915 |
| UVA Light Emitting Catheter | DEVICE | Approved | COVID-19 Pneumonia | WITHDRAWN | NCT05166915 |
| UV Light Treatment | DEVICE | Approved | Coronavirus | COMPLETED | NCT04572399 |
| SPECT-CT | DEVICE | Approved | Prostate Cancer | COMPLETED | NCT02786459 |
| Magnetic Resonance Imaging | DEVICE | Approved | Prostate Cancer | COMPLETED | NCT02786459 |
| ProxiScan | DEVICE | Approved | Prostate Cancer | COMPLETED | NCT02786459 |